

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

Review of NICE Technology Appraisal; Adalimumab, etanercept, infliximab, rituximab, abatacept (review of TA195), golimumab (part review of TA225) and tocilizumab (part review of TA247) for the treatment of rheumatoid arthritis after failure of disease-modifying anti-rheumatic drugs including a TNF-inhibitor

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Bristol Myers Squibb (abatacept) • Merck Sharp & Dohme (infliximab, golimumab) • Pfizer (etanercept) • Roche Products (rituximab, tocilizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Afiya Trust • Arthritic Association • Arthritis and Musculoskeletal Alliance • Arthritis Care • Back Care • Black Health Agency • Disability Rights UK • Equalities National Council • Independent Age • Leonard Cheshire Disability • Muslim Council of Britain • Muslim Health Network • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Surgeons of Great Britain and Ireland • British Association for Services to the Elderly 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Actavis UK (azathioprine, leflunomide) • Arrow Generics (azathioprine) • Aspen (azathioprine) • Bristol Laboratories (hydroxychloroquine) • Creo Pharma (hydroxychloroquine) • Crescent Pharma (sulfasalazine) • Dexcel Pharma (cyclosporin) • Hameln Pharmaceutical (methotrexate) • Hospira UK (methotrexate) • Medac UK (leflunomide, methotrexate) • Mercury Pharma Group (methotrexate) • Mylan (azathioprine, cyclosporin, sulfasalazine, penicillamine)

<ul style="list-style-type: none"> • British Geriatrics Society • British Health Professionals in Rheumatology • British Institute of Musculoskeletal Medicine • British Institute of Radiology • British Orthopaedic Association • British Pain Society • British Society for Rheumatology • British Society of Rehabilitation Medicine • Physiotherapy Pain Association • Primary Care Rheumatology Society • Rheumatoid Arthritis Surgical Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Stafford and Surrounds CCG • NHS Warrington CCG • Welsh Government 	<ul style="list-style-type: none"> • Novartis (ciclosporin) • Orion Pharma (UK) (methotrexate) • Pfizer (methotrexate, sulfasalazine, tofacitinib) • Rosemont Pharmaceuticals (sulfasalazine) • Sandoz (azathioprine, leflunomide, methotrexate) • Sanofi (hydroxychloroquine, leflunomide, sodium aurothiomalate) • Teva UK (azathioprine, ciclosporin, hydroxychloroquine, leflunomide, methotrexate, penicillamine, sulfasalazine) • UCB Pharma (certolizumab pegol) • Wockhardt (methotrexate) • Zentiva UK (leflunomide) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Arthritis Research UK • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Musculoskeletal Group • Health Research Authority • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People • The Work Foundation <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • None <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.